Philip Buck leads the US Health Outcomes team at GSK Vaccines. Phil has over 15 years experience in healthcare research, with a focus on epidemiology, health economics, and psychometrics. He earned an MA and PhD in health psychology from Wayne State University and an MPH in epidemiology from the University of California, Berkeley. After post-doctoral training in infectious disease, Phil led a research team for a start-up research and consulting company and then held various positions of increasing responsibility in global health economics and outcomes research at Teva Pharmaceuticals. Phil joined US Health Outcomes at GSK in 2013, initially supporting oncology before moving to the US vaccines team in 2014. His previous vaccines responsibilities have included designing and implementing health outcomes strategies for GSK’s pertussis, influenza, and herpes zoster vaccines.